Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

BTIG Maintains Buy on DermTech, Lowers Price Target to $2

Author: Benzinga Newsdesk | March 07, 2024 12:42pm
BTIG analyst Mark Massaro maintains DermTech (NASDAQ:DMTK) with a Buy and lowers the price target from $4 to $2.

Posted In: DMTK

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist